^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Belrapzo (bendamustine RTD)

    i
    Other names: EP-3101
    Company:
    Eagle Pharma, SymBio Pharma
    Drug class:
    Alkylating agent
    Related drugs:
    10d
    SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD)
    3ms
    CALGB-50904: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=135, Completed, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Sep 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule)
    |
    bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)
    4ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    10ms
    CALGB-50904: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=135, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule)
    |
    bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)
    11ms
    ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=547, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Mabtas (rituximab biosimilar)
    12ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    1year
    MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Fox Chase Cancer Center | Trial completion date: Sep 2027 --> Mar 2028 | Initiation date: Dec 2024 --> Jun 2025 | Trial primary completion date: Mar 2027 --> Sep 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • ondansetron intravenous
    over1year
    waveLINE-003: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (clinicaltrials.gov)
    P2/3, N=290, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • zilovertamab vedotin (MK-2140) • Belrapzo (bendamustine RTD)
    over1year
    MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Fox Chase Cancer Center | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date
    |
    Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • ondansetron intravenous
    over1year
    MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Fox Chase Cancer Center
    New P2 trial
    |
    Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • ondansetron intravenous
    over1year
    SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD)
    almost2years
    A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (clinicaltrials.gov)
    P2/3, N=260, Recruiting, Merck Sharp & Dohme LLC | N=420 --> 260 | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • zilovertamab vedotin (MK-2140) • Belrapzo (bendamustine RTD)